RhumbLine Advisers’s PRA Health Sciences, Inc. PRAH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-174,043
| Closed | -$28.8M | – | 3067 |
|
|
2021
Q2 | $28.8M | Sell |
174,043
-2,571
| -1% | -$429K | 0.04% | 434 |
|
|
2021
Q1 | $27.1M | Sell |
176,614
-2,286
| -1% | -$310K | 0.04% | 454 |
|
|
2020
Q4 | $22.4M | Sell |
178,900
-4,389
| -2% | -$491K | 0.03% | 496 |
|
|
2020
Q3 | $18.6M | Sell |
183,289
-5,325
| -3% | -$543K | 0.03% | 498 |
|
|
2020
Q2 | $18.4M | Buy |
188,614
+17,476
| +10% | +$1.63M | 0.03% | 480 |
|
|
2020
Q1 | $14.2M | Sell |
171,138
-1,646
| -1% | -$161K | 0.03% | 517 |
|
|
2019
Q4 | $19.2M | Buy |
172,784
+1,205
| +0.7% | +$124K | 0.03% | 503 |
|
|
2019
Q3 | $17M | Buy |
171,579
+5,737
| +3% | +$570K | 0.03% | 514 |
|
|
2019
Q2 | $16.4M | Buy |
165,842
+3,399
| +2% | +$324K | 0.03% | 527 |
|
|
2019
Q1 | $17.9M | Buy |
162,443
+2,714
| +2% | +$284K | 0.03% | 487 |
|
|
2018
Q4 | $14.7M | Buy |
159,729
+45,356
| +40% | +$4.59M | 0.03% | 537 |
|
|
2018
Q3 | $12.6M | Buy |
114,373
+10,080
| +10% | +$1.05M | 0.02% | 584 |
|
|
2018
Q2 | $9.74M | Buy |
104,293
+56,791
| +120% | +$4.89M | 0.02% | 693 |
|
|
2018
Q1 | $3.94M | Sell |
47,502
-1,691
| -3% | -$150K | 0.01% | 1206 |
|
|
2017
Q4 | $4.48M | Sell |
49,193
-7,753
| -14% | -$645K | 0.01% | 1135 |
|
|
2017
Q3 | $4.34M | Buy |
56,946
+12,797
| +29% | +$967K | 0.01% | 1117 |
|
|
2017
Q2 | $3.31M | Buy |
44,149
+14,413
| +48% | +$999K | 0.01% | 1253 |
|
|
2017
Q1 | $1.94M | Buy |
29,736
+1,346
| +5% | +$79.3K | ﹤0.01% | 1573 |
|
|
2016
Q4 | $1.56M | Buy |
28,390
+1,289
| +5% | +$70.7K | ﹤0.01% | 1595 |
|
|
2016
Q3 | $1.53M | Buy |
27,101
+2,238
| +9% | +$110K | ﹤0.01% | 1577 |
|
|
2016
Q2 | $1.04M | Buy |
24,863
+3,877
| +18% | +$179K | ﹤0.01% | 1764 |
|
|
2016
Q1 | $897K | Buy |
20,986
+260
| +1% | +$11K | ﹤0.01% | 1864 |
|
|
2015
Q4 | $938K | Buy |
20,726
+2,535
| +14% | +$107K | ﹤0.01% | 1847 |
|
|
2015
Q3 | $706K | Buy |
18,191
+556
| +3% | +$22.3K | ﹤0.01% | 2004 |
|
|
2015
Q2 | $641K | Buy |
17,635
+1,405
| +9% | +$44.4K | ﹤0.01% | 2167 |
|
|
2015
Q1 | $468K | Buy |
+16,230
| New | +$453K | ﹤0.01% | 2336 |
|
Other funds holding PRAH
RhumbLine Advisers's PRAH Position: Q3 2021 in Review
RhumbLine Advisers sold out of PRA Health Sciences, Inc. (PRAH) in Q3 2021, closing a stake of 174,043 shares — an estimated $28.8M sold.
RhumbLine Advisers first reported a position in PRAH in Q1 2015 and held it in 26 quarters. The position peaked at $28.8M in Q2 2021. 1 fund tracked by Wall St. Rank holds PRAH as of Q3 2021.
- RhumbLine Advisers reported no remaining PRA Health Sciences, Inc. position as of Q3 2021 after selling out during the quarter.
- RhumbLine Advisers sold 174,043 PRA Health Sciences, Inc. shares in Q3 2021, an estimated $28.8M.
- RhumbLine Advisers first reported a position in PRA Health Sciences, Inc. in Q1 2015 and held it in 26 quarters.
- RhumbLine Advisers's PRA Health Sciences, Inc. position peaked at $28.8M in Q2 2021.
- 1 fund tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q3 2021.
Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.